62
Participants
Start Date
March 31, 2004
Primary Completion Date
May 31, 2005
Study Completion Date
May 31, 2005
Botulinum Toxin Type A
200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18
Placebo
Saline injection on Day 0
Indianapolis
Lead Sponsor
Allergan
INDUSTRY